Navigation Links
AlphaDetail AlphaPulse(TM): Most Practicing Physicians React Positively to FDA Panel's Recommendation for Additional Cardiovascular Safety Trials for New Diabetes Medications.
Date:7/8/2008

SAN MATEO, Calif., July 8 /PRNewswire/ -- After meeting on July 1st and 2nd an FDA advisory panel recommended that all new diabetes drugs should undergo trials to rule out cardiovascular risk. 85% of US cardiologists and 65% of US endocrinologists agree with this recommendation, according to AlphaDetail Inc., a leader in cardiovascular and metabolic primary market research and key opinion leader mapping solutions to the Global Life Sciences Industry.

On July 3rd AlphaDetail launched its latest AlphaPulse(TM) survey to measure immediate physician awareness and reactions to the panel recommendation. In a brief on-line survey of 52 cardiologists and 51 endocrinologists AlphaDetail found:

-- Unaided, about 40% of physicians mentioned CV risk associated with

diabetes medications as the most important development in diabetes

treatment from the past month.

-- When prompted, half of physicians indicated they had heard about the

FDA panel recommendation to require cardiovascular safety trials for

new diabetes medications -- only a day after the news was announced.

-- Although most physicians from both specialties support the

recommendation, twice as many cardiologists (33%) vs. endocrinologists

(16%) agree strongly with it.

-- However, 22% of endocrinologists disagree with the

recommendation primarily because they believe it would stifle

innovation and delay the availability of important new

therapies.

-- Physicians disagree on the most appropriate implementation of the FDA

panel recommendation -- two CV safety trials vs. only one trial.

-- However, more physicians believe that the two trial

implementation is the most appropriate.

-- Even so, a segment of physicians (25% of cardiologists and 37% of

endocrinologists) would support prescribing a new diabetes therapy that

is highly efficacious but has CV risk to patients that have no CV risk

factors other than diabetes.

-- Physicians have to make a trade-off between controlling diabetes

and preventing other diabetes complications vs. preventing CV

risk.

To learn more about this study, please contact Bob Latshaw at Bob.Latshaw@alphadetail.com or (215) 259-5601.

About AlphaDetail, Inc.:

At AlphaDetail, we have an unparalleled commitment to our clients. We are a full-service primary market research firm, with a particular emphasis in large and complex quantitative studies for the global healthcare community. AlphaDetail is built on one of the industry's strongest foundations that includes a large team of exceptional analytical specialists, the industry's leading technology platform and a flexible approach to research that helps us answer our client's most challenging questions.


'/>"/>
SOURCE AlphaDetail, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Mayo Clinic Physicians Report Findings from Research on Sleep Disorders
2. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
3. Leading Physicians Present Interim Results from Multi-Center Studies of VNUS ClosureFAST Catheter at VEITHsymposium
4. Physicians Will Benefit from Medical Software Advice Website
5. Physicians Reconsider Implications of Enhance Trial
6. US Oncology Affiliated Physicians Make a Strong Showing in ASCO Proceedings
7. ISAR-REACT 3 Pits Bivalirudin vs. Unfractionated Heparin in PCI
8. Influenza is Leading Cause of Vaccine-Preventable Deaths for Kids; Despite CDC Recommendations, Moms Still Dont Vaccinate
9. New Report by Pediatricians Finds Gaps in Preparing to Protect Kids From Pandemic Flu, Offers Recommendations
10. UPDATE: New Report by Pediatricians Finds Gaps in Preparing to Protect Kids From Pandemic Flu, Offers Recommendations
11. American Meat Institute Calls WCRF Panel Recommendations on Meat Consumption Extreme and Unfounded
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that it ... (procalcitonin) assay as a dedicated testing solution for people ... Roche is the first IVD company in the U.S ... assessment and management. PCT is a sepsis-specific ... blood can aid clinicians in assessing the risk of ...
(Date:6/23/2016)... Research and Markets has announced the addition of the ... offering. The current unmet ... for MedImmune to enter. The US ageing population creates a ... considerable growth for effective anti-influenza medications. The introduction of a ... development is still in its infancy. Key ...
(Date:6/23/2016)... and INDIANAPOLIS , June ... receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is any ... scholarship winners, announced today online at www.diabetesscholars.org ... type 1 diabetes stand in the way of academic ... supported the Foundation,s scholarship program since 2012, and continues ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, ... and his M.D from the David Geffen School of Medicine at UCLA. He trained ... Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where ...
(Date:6/24/2016)... ... June 24, 2016 , ... A recent article published June ... with. The article goes on to state that individuals are now more comfortable seeking ... common operations such as calf and cheek reduction. The Los Angeles area medical group, ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary ... Dallas that it will receive two significant new grants to support its work ... marked its 25th anniversary by recognizing patients, medical professionals and scientists for their ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain ... for a minimum wage raise to $12 an hour by 2020 and then adjusting it ... the lost value of the minimum wage, assure the wage floor does not erode again, ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... The Grove Investment Group (TGIG), has initiated cultivation and processing operations at its ... Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system ...
Breaking Medicine News(10 mins):